Microbial growth on temporary pacemaker leads post-TAVR: pathogen spectrum and clinical implications
-
Published:2024-09-10
Issue:
Volume:
Page:
-
ISSN:1861-0684
-
Container-title:Clinical Research in Cardiology
-
language:en
-
Short-container-title:Clin Res Cardiol
Author:
Mousa Basha MustafaORCID, Al-Kassou Baravan, Gestrich Christopher, Weber Marcel, Beiert Thomas, Bakhtiary Farhad, Nickenig Georg, Zimmer Sebastian, Shamekhi Jasmin
Abstract
Abstract
Background and objective
Transcatheter aortic valve replacement (TAVR) is an established treatment option for patients with symptomatic severe aortic stenosis across all stages of surgical risk. Rapid pacing during the procedure and the risk for the occurrence of conduction disturbances after TAVR requires the pre-interventional insertion of a temporary pacemaker (TP). However, this approach poses risks, including the risk of infection. For this reason, the following study aimed to investigate microbial growth on temporary pacemaker leads and its association with outcome post-TAVR and to identify associated pathogens and related risk factors.
Methods
A prospective study was conducted including 344 patients undergoing TAVR at the Heart Centre Bonn. Of these, 97 patients did not require TP leads as they already had permanent pacemakers; this group was considered as comparison group. The TP leads of the remaining 247 patients were removed, sonicated, and cultured to investigate bacterial growth over a period of 14 days. Finally, we compared patients without microbial growth (n = 184) and patients with microbial growth (n = 63). The primary endpoint of the study was 30-day all-cause mortality, secondary endpoints were periprocedural infections, the length of the postprocedural hospital stay, 30-day major vascular complications and the 30-day stroke rate.
Results
The majority of cases (74.5%) showed no bacterial growth. In the remaining cases (25.5%), diverse microorganisms were identified, mostly non-pathogenic bacteria. The statistical analysis revealed no significant differences between groups according to microbial growth in terms of 30-day mortality (p = 0.446), postprocedural hospital stay (p = 0.401), periprocedural infections (p = 0.434), 30-day major vascular complications (p = 1.0), and 30-day stroke rate (p = 1.0). Notably, the timing of sheath insertion was significantly associated with microbial growth; sheath placement more than 2 days prior to the procedure was associated with a significantly higher risk of microbial growth (OR: 2.1; 95% CI 1.1–4.3) (p = 0.030).
Conclusions
The presence of temporary leads does not significantly impact clinical outcomes, irrespective of bacterial growth on the lead. However, the timing and duration of sheath placement plays a crucial role in contamination incidence. Thus, temporary leads/sheaths should be placed shortly before the procedure and removed promptly to reduce the risk of contamination/infection.
Funder
Deutsche Forschungsgemeinschaft Universitätsklinikum Bonn
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363(17):1597–607. https://doi.org/10.1056/NEJMoa1008232 2. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb JG, Douglas PS, Anderson WN, Blackstone EH, Kodali SK, Makkar RR, Fontana GP, Kapadia S, Bavaria J, Hahn RT, Thourani VH, Babaliaros V, Pichard A, Herrmann HC, Brown DL, Williams M, Akin J, Davidson MJ, Svensson LG, PARTNER 1 trial investigators (2015) 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385(9986):2477–84. https://doi.org/10.1016/S0140-6736(15)60308-7 3. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, Weissman NJ, Rodriguez L, Xu K, Annabi MS, Guzzetti E, Beaudoin J, Bernier M, Leipsic J, Blanke P, Clavel MA, Rogers E, Alu MC, Douglas PS, Makkar R, Miller DC, Kapadia SR, Mack MJ, Webb JG, Kodali SK, Smith CR, Herrmann HC, Thourani VH, Leon MB, Hahn RT, PARTNER 2 Investigators (2020) Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial. J Am Coll Cardiol 76(16):1830–1843. https://doi.org/10.1016/j.jacc.2020.08.049 4. López Ayerbe J, Villuendas Sabaté R, García García C, Rodríguez Leor O, Gómez Pérez M, Curós Abadal A, Serra Flores J, Larrousse E, Valle V (2004) Marcapasos temporales: utilización actual y complicaciones [temporary pacemakers: current use and complications]. Rev Esp Cardiol 57(11):1045–1052 5. Polyzos KA, Konstantelias AA, Falagas ME (2015) Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace 17(5):767–777. https://doi.org/10.1093/europace/euv053
|
|